You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

The Use of Imatinib Mesylate (GleevecTM) in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Patient Population

Adult patients with newly diagnosed or relapsed or refractory imatinib/dasatinib-naive Ph+ ALL.

Research Question(s)

Does treatment with imatinib mesylate (imatinib) in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) or relapsed/refractory imatinib/dasatinib naïve Ph+ ALL affect overall survival, progression free survival, response, quality of life, and adverse events?

pdf download pebcced10f.pdf
Modality: 

Biological Therapy

PEBC: 

PEBC

Guideline Identifier: 

CED 10

Cancer Continuum: 

Treatment

Cancer Type: 

Hematologic

Leukemia

Type of Content: 

Guidelines & Advice

Clinical

Authors:  I. Walker C.T. Kouroukis A.E. Haynes K. Imrie Universal Date:  2008-09-29 00:00:00